MedTrace Logo

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)

NCT02597868 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2016-03-29

No results posted yet for this study

Summary

A multi-sites study about the efficacy of sequential monotherapy: Capecitabine vs. endocrine therapy, in metastatic breast cancer patients with HR-positive \& HER2-negative after capecitabine-base chemotherapy.

Conditions

Interventions

DRUG

Capecitabine

Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.

PROCEDURE

endocrine therapy

endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.

Sponsors & Collaborators

  • 307 Hospital of PLA

    collaborator OTHER

  • Fudan University

    collaborator OTHER

  • The Tumor Hospital of Jiangsu Province

    collaborator OTHER

  • Fujian Province Tumor Hospital

    collaborator OTHER

  • Zhejiang University

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Zhejiang Chinese Medical University

    collaborator OTHER_GOV

  • Hangzhou Cancer Hospital

    collaborator OTHER

  • Jiangsu Provincial People's Hospital

    collaborator OTHER

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Xiaojia Wang, PHD · Zhejiang Cance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-07-31
Completion
2017-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02597868 on ClinicalTrials.gov